3rd Generation Appointed Chairman of the Board of Directors of Vetoquinol SA
May 25 2023 - 11:45AM
Business Wire
Regulatory News:
The Combined General Meeting of Vetoquinol (Paris:VETO)
shareholders was held on Thursday 25 May 2023 at the laboratory's
head office in Lure (Franche-Comté), chaired by Mr. Etienne
Frechin.
All the resolutions proposed by the Board of Directors were
adopted, including:
- The statutory and consolidated financial statements for the
year 2022 were approved.
- The dividend per share was set at 0.80 euro. It will be paid as
of 6 June 2023.
- The reappointment of Mr. Philippe Arnold as an independent
director and the appointment of Mrs. Anne-Marie Graffin as a new
independent director.
- The detailed results of the votes will be available on
Vetoquinol's website from 26 May 2023 in the "General Meetings"
section.
At the Combined General Meeting it was also announced that Mr.
Etienne Frechin will resign as Chairman of the Board of Vetoquinol,
effective 1st July 2023. Mr. Etienne Frechin will remain a Director
of the company, hence continuing to share his broad experience. On
25 May 2023, the Board of Directors appointed Mr. Matthieu Frechin,
Chief Executive Officer of the Group, as Chairman of the Board of
Directors of Vetoquinol effective 1st July 2023.
The Board of Directors unanimously acknowledged Mr. Etienne
Frechin's substantial contribution to the success and international
development of the company over the sixty years he has been in
office.
Etienne Frechin, son of Joseph Frechin, founder of Vetoquinol,
has spent his entire professional career at the company, where he
has successively held the positions of Production Director, General
Manager, Chairman and CEO and, since 1980, Chairman of the Board of
Directors. Throughout his career, he has accompanied the very
strong growth of the laboratory and led multiple development
operations in France and abroad in order to create one of the top
10 international players in animal health. In 2006, he also
successfully completed the company IPO, increasing the laboratory's
reputation and sharing his vision of the animal health
business.
Next update: Half-Yearly Results, September 7, 2023
ABOUT VETOQUINOL Vetoquinol is a leading global animal health
company that supplies drugs and non-medicinal products for the farm
animals (cattle and pigs) and pet (dogs and cats) markets. As an
independent pure player, Vetoquinol designs, develops and sells
veterinary drugs and non-medicinal products in Europe, the Americas
and the Asia Pacific region. Since its foundation in 1933,
Vetoquinol has pursued a strategy combining innovation with
geographical diversification. The Group’s hybrid growth is driven
by the reinforcement of its product portfolio coupled with
acquisitions in high potential growth markets. Vetoquinol employed
2,521 people as of December 31st, 2022.
Vetoquinol has been listed on Euronext Paris since 2006 (symbol:
VETO). The Vetoquinol share is eligible for the French PEA and
PEA-PME personal equity plans.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230525005574/en/
FOR MORE INFORMATION, CONTACT:
VETOQUINOL
Investor Relations Fanny Toillon Tel.: +33 (0)3 84
62 59 88 relations.investisseurs@vetoquinol.com
KEIMA COMMUNICATION
Investor & Media Relations Emmanuel Dovergne
Tel.: +33 (0)1 56 43 44 63 emmanuel.dovergne@keima.fr
Vetoquinol (EU:VETO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vetoquinol (EU:VETO)
Historical Stock Chart
From Jul 2023 to Jul 2024